-
Posted by
Two Blokes Jul 25 -
Filed in
Stock
-
1 view
Agreement covers contract development and manufacturing of lead compound PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL\u00ae gene silencing technology to eliminate cancer. Phio announced today it has entered into a comprehensive drug substance development services agreement with a U.S. manufacturer.
